Data di Pubblicazione:
2023
Citazione:
Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers / C. Sorino, M. Mondoni, G. Marchetti, S. Agati, R. Inchingolo, F. Mei, S. Flamini, F. Lococo, D. Feller-Kopman. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 12:22(2023), pp. 7006.1-7006.21. [10.3390/jcm12227006]
Abstract:
Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos
fibers. It shows aggressive behavior, and the current therapeutic approaches are usually insufficient
to change the poor prognosis. Moreover, apart from staging and histological classification, there are
no validated predictors of its response to treatment or its long-term outcomes. Numerous studies
have investigated minimally invasive biomarkers in pleural fluid or blood to aid in earlier diagnosis
and prognostic assessment of PM. The most studied marker in pleural effusion is mesothelin, which
exhibits good specificity but low sensitivity, especially for non-epithelioid PM. Other biomarkers
found in pleural fluid include fibulin-3, hyaluronan, microRNAs, and CYFRA-21.1, which have lower
diagnostic capabilities but provide prognostic information and have potential roles as therapeutic
targets. Serum is the most investigated matrix for biomarkers of PM. Several serum biomarkers
in PM have been studied, with mesothelin, osteopontin, and fibulin-3 being the most often tested.
A soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker in patients
with suspected mesothelioma. With different serum and pleural fluid cut-offs, it provides useful
information on the diagnosis, prognosis, follow-up, and response to therapy in epithelioid PM. Panels
combining different markers and proteomics technologies show promise in terms of improving
clinical performance in the diagnosis and monitoring of mesothelioma patients. However, there is
still no evidence that early detection can improve the treatment outcomes of PM patients.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
mesothelioma; pleural effusion; biomarkers; mesothelin; fibulin-3
Elenco autori:
C. Sorino, M. Mondoni, G. Marchetti, S. Agati, R. Inchingolo, F. Mei, S. Flamini, F. Lococo, D. Feller-Kopman
Link alla scheda completa: